PUBLICATIONS

Publications on Orphan Drugs

  1. Ardigò, D, Bianchi, F, Bosio, MC, Simonini, A, Farahani, M, Dallaglio, K et al.. Unveiling the depth of the knowledge gap in the Universe of Rare Diseases: the PLUTO mission. Orphanet J Rare Dis. 2026;21 (1):. doi: 10.1186/s13023-026-04574-1. PubMed PMID:43058741 .
  2. Wang, L, Yang, M, Wang, S, Gu, S, Tong, R, Zhou, M et al.. Factors impacting cost-effectiveness results: evidence from rare diseases listed in China's rare disease catalogues. BMC Health Serv Res. 2026;26 (1):. doi: 10.1186/s12913-026-15418-w. PubMed PMID:43053017 PubMed Central PMC13783690.
  3. Gullaksen, SE, Brevik, M, Craig, E, Hellesøy, M, Sefland, Ø, Olsson-Strömberg, U et al.. Deep single-cell immune- and signaling profiles predict therapy response in chronic myeloid leukemia within hours. Signal Transduct Target Ther. 2026;11 (1):. doi: 10.1038/s41392-026-03070-z. PubMed PMID:43045686 PubMed Central PMC13778230.
  4. Joy, J, Suresh, J, Chhakra, U, Shukla, S, Vivekanandan, K. Rare diseases and orphan therapies in India: burden and pharmacopeial considerations. J Community Genet. 2026;17 (6):. doi: 10.1007/s12687-026-00972-x. PubMed PMID:43020952 PubMed Central PMC13759942.
  5. Wan, M, Shroff, R, Atanackovic, G, Böckenhauer, D, Arjona, SC, Cavaller-Bellaubi, M et al.. A roadmap for therapeutic innovation in paediatric chronic kidney disease. Nat Rev Nephrol. 2026; :. doi: 10.1038/s41581-026-01148-z. PubMed PMID:43020879 .
  6. Chen, D, Wen, G, Xu, S, Zhang, Q. Admission patterns and clinical management of rare diseases in 46 pediatric intensive care units across China: a multicenter survey. Front Pediatr. 2026;14 :1983050. doi: 10.3389/fped.2026.1983050. PubMed PMID:43016923 PubMed Central PMC13752003.
  7. Hagg, A, Reith, D, Preller, M, Kirschner, KN. Molecular function-guided unsupervised similarity-based enrichment for low-data virtual screening. J Cheminform. 2026;18 (1):. doi: 10.1186/s13321-026-01326-y. PubMed PMID:43004465 PubMed Central PMC13750033.
  8. Arava, M, Sivankutty, I, Kim, JH, An, Z, Hilal, N, Matsui, E et al.. Assessment of cellular and molecular pathways in the human fibrotic precision cut lung slice after cryopreservation. Dis Model Mech. 2026; :. doi: 10.1242/dmm.052773. PubMed PMID:42992462 .
  9. McDonnell, A, Geraghty, M, Oltmanns, E, McDermott, O, Melvin, T. Pathways to first clinical use of a medical device in the United States and the European Union: a narrative review. Expert Rev Med Devices. 2026; :1-12. doi: 10.1080/17434440.2026.2760004. PubMed PMID:42989485 .
  10. Ni, J, Yan, Y, Zhang, L. The impact of national reimbursement drug negotiation on hospital procurement of rare disease drugs: an interrupted time series analysis. Int J Equity Health. 2026;25 (1):. doi: 10.1186/s12939-026-02974-0. PubMed PMID:42983751 PubMed Central PMC13733122.
  11. Sultan, I, Paubel, P, Degrassat-Théas, A. Reimbursement status, access delays and prices of orphan drugs in France: a population-stratified analysis of indications approved between 2021 and 2024. Orphanet J Rare Dis. 2026;21 (1):. doi: 10.1186/s13023-026-04533-w. PubMed PMID:42983542 PubMed Central PMC13732822.
  12. Sevim, F, Akyürek, ÇE. Access without published appraisal: orphan medicine reimbursement and health equity in Türkiye. Eur J Public Health. 2026;36 (6):. doi: 10.1093/eurpub/ckag204. PubMed PMID:42981499 PubMed Central PMC13734380.
  13. Kuntz, C. Orphan Blockbuster Drug Development. Health Aff (Millwood). 2026;45 (11):1308. doi: 10.1377/hlthaff.2026.01330. PubMed PMID:42970726 .
  14. Unterberger, U, Bruyère-Zrelli, J, Lucas, T, Voigtländer, T, Rath, A. Clinical trials on rare diseases in Austria 2011-2021: a study using the orphanet database. Orphanet J Rare Dis. 2026;21 (1):. doi: 10.1186/s13023-026-04673-z. PubMed PMID:42963554 PubMed Central PMC13721337.
  15. Wu, M, Tang, G, Liu, M, Wang, X, Xie, Y, Wu, Y et al.. Repurposing the orphan drug nitisinone synergizes with sorafenib to sensitize immunotherapy-refractory MSS-CRC via metabolic stress-driven STING activation. Pharmacol Res. 2026;234 :109724. doi: 10.1016/j.phrs.2026.109724. PubMed PMID:42963013 .
  16. Yogeswaran, A, Berger, M, De Bie, E, Kiely, DG, Annis, JS, Hassoun, PM et al.. Systemic Hypertension and Survival in Pulmonary Hypertension. JAMA Cardiol. 2026; :. doi: 10.1001/jamacardio.2026.4834. PubMed PMID:42961442 PubMed Central PMC13723037.
  17. Chen, L, Chen, J, Li, C, Jiang, L, Liu, Y. Uncovering a cryptic allosteric hub governing energy landscape plasticity within the Nur77 ligand-binding domain. Magn Reson Lett. 2027;7 (4):200312. doi: 10.1016/j.mrl.2026.200312. PubMed PMID:42960295 PubMed Central PMC13718860.
  18. Shukan, EY, Komarov, IA, Aleksandrova, OY, Smirnova, NS. [The analysis of organization of medical care of wards of the foundation "The circle of Good" using orphan medications]. Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2026;34 (5):1300-1305. doi: 10.32687/0869-866X-2026-34-5-1300-1305. PubMed PMID:42954212 .
  19. Jain, U, Polkampally, S, Jadav, AA, Jain, B, Jain, P, Haumschild, R et al.. Value-Based Care Contracting for Pharmacy Drugs: Opportunity for the United States. Value Health. 2026; :. doi: 10.1016/j.jval.2026.08.014. PubMed PMID:42918324 .
  20. Yamaguchi, S, Nakatani, E, Asada, R. Investigator-Initiated Trials as a Clinical Development Approach for Orphan Drugs Compared with Industry-Sponsored Trials in Japan. Ther Innov Regul Sci. 2026; :. doi: 10.1007/s43441-026-01063-2. PubMed PMID:42909798 .
Search PubMed